Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–1657.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42; quiz e30.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.
   PubMed Web of Science ®Google Scholar
• Floyd DN, Langham S, Séverac HC, et al. The economic and quality-of-life burden of Crohn’s disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci. 2015;60(2):299–312.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study. Gut. 2014;63(1):72–79.
   PubMed Web of Science ®Google Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Bjerrum JT, Seidelin JB, et al. Biological treatment of Crohn’s disease. Dig Dis. 2012;30(Suppl 3):121–133.
   PubMed Web of Science ®Google Scholar
• Baji P, Gulácsi L, Lovász BD, et al. Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scand J Gastroenterol. 2016;51(1):22–27.
   PubMed Web of Science ®Google Scholar
• Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756.
   PubMed Web of Science ®Google Scholar
• Rencz F, Péntek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728–1737.
   PubMed Web of Science ®Google Scholar
• Boncz I, Sebestyén A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006;368(9539):917–918.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2016;14:22–31.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lakatos PL. Biosimilar monoclonal antibodies for inflammatory bowel disease: current comfort and future prospects. Drugs. 2016;76(15):1413–1420.
   PubMed Web of Science ®Google Scholar
• Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–1262.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–1712.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Rencz F, Péntek M, et al. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–125.
   PubMed Web of Science ®Google Scholar
• Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS One. 2015;10(12):e0145087.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Alfonso-Cristancho R, Carlson J, et al. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ. 2013;16(3):391–396.
   PubMedGoogle Scholar
• Tosh J, Stevenson M, Akehurst R. Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. Curr Rheumatol Rep. 2014;16(10):447.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333; quiz 591.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Int Med. 2007;146(12):829–838.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6(2):160–173.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–1035.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–1111.e2.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–769.
   PubMed Web of Science ®Google Scholar
• Laji J. Biológiai terápia 2006–2010. Elemzés. National Health Insurance Fund Administration of Hungary Department of Medical Expertise, Clinical Auditing and Analysis; 2012.
   Google Scholar
• Eurostat. Life tables. 2014; [cited 2015 Sep 9]. Available from: http://ec.europa.eu/eurostat/web/population-demography-migration-projections/deaths-life-expectancy-data/database#
   Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–630.
   PubMed Web of Science ®Google Scholar
• Rafia R, Scope A, Harnan S, et al. Vedolizumab for the treatment of adults with moderately to severely active Crohn’s disease: a single technology appraisal. School of Health and Related Research (ScHARR); Sheffield, UK, 2014.
   Google Scholar
• Rafia R, Scope A, Harnan S, et al. Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2016;34:1241–1253.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis. Aliment Pharmacol Ther. 2010;31(7):735–744.
   PubMed Web of Science ®Google Scholar
• Rijksinstituut voor ziekte- en invaliditeitsverzekering. Specialités pharmaceutiques – liste de prix et base de remboursement. 2016; [cited 2016 May 18]. Available from: http://www.inami.fgov.be/SiteCollectionDocuments/liste-specialites-prices-20160501.pdf
   Google Scholar
• La base de données en ligne des prescripteurs libéraux. 2016; [cited 2016 May 18]. Available from: https://www.vidal.fr
   Google Scholar
• Medipreis. Preisvergleich für Medikamente. 2016; [cited 2016 May 18]. Available from: https://www.medipreis.de
   Google Scholar
• National Health Insurance Fund Administration of Hungary. National price list of pharmaceuticals. 2015; [cited 2016 May 18]. Available from: http://www.oep.hu//data/cms1009157/PUPHA_20151201_v3.zip
   Google Scholar
• Medicina e Società. 2016; [cited 2016 May 18]. Available from: http://www.medisoc.it
   Google Scholar
• Medicijnkosten. 2016; [cited 2016 May 18]. Available from: http://www.medicijnkosten.nl
   Google Scholar
• Nomenclator.org Información sobre medicamentos. 2016; [cited 2016 May 19]. Available from: http://a.nomenclator.org
   Google Scholar
• Swedish Dental and Pharmaceutical Benefits Agency (TLV) 2016; [cited 2016 May 18]. Available from: http://www.tlv.se/In-English/medicines-new/
   Google Scholar
• British National Formulary (BNF) 71. 2016; [cited 2016 May 18]. Available from: https://www.evidence.nhs.uk/formulary/bnf/current
   Google Scholar
• International Society For Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world; [ cited 2016 Jun 28]. Available from: http://www.ispor.org/peguidelines/index.asp
   Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674–684.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Choosing interventions that are cost-effective. Geneva: World Health Organization; 2014.
   Google Scholar
• The World Bank. GDP per capita (current US$); [ cited 2016 May 31]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD
   Google Scholar
• Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis. 1997;3(4):265–276.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Lacey LA, Feagan BG, et al. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value Health. 2007;10(3):214–220.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Schwartz D, Vardi H, et al. Health-related utility weights in a cohort of real-world Crohn’s disease patients. J Crohns Colitis. 2015;9(12):1138–1145.
   PubMed Web of Science ®Google Scholar
• Assasi N, Blackhouse G, Xie F et al. Anti-TNF-α drugs for refractory inflammatory bowel disease: clinical- and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. (Technology report number 120).
   Google Scholar
• Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease. J Crohns Colitis. 2012;6(1):77–85.
   PubMed Web of Science ®Google Scholar
• Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotherapy. 2012;32(6):515–526.
   PubMed Web of Science ®Google Scholar
• Yu AP, Johnson S, Wang S-T, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27(7):609–621.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig Dis Sci. 2012;57(2):472–480.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Malinowski KP. Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):253–266.
   PubMed Web of Science ®Google Scholar
• Zand A, van Deen WK, Inserra EK, et al. Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis. 2015;21(7):1623–1630.
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Chen J, Rizzo JA, et al. The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. J Occup Environ Med. 2013;55(4):393–401.
   PubMed Web of Science ®Google Scholar
• Mandel MD, Balint A, Lovasz BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014;15(Suppl 1):S121–S128.
   PubMed Web of Science ®Google Scholar
• Murdoch T, O’Donnell S, Silverberg MS, et al. Biomarkers as potential treatment targets in inflammatory bowel disease: a systematic review. Can J Gastroenterol Hepatol. 2015;29(4):203–208.
   PubMed Web of Science ®Google Scholar
• Barnes EL, Burakoff R. New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes. Inflamm Bowel Dis. 2016;22(12):2956–2965.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] members: an updated survey. J Crohns Colitis. 2016;10(11):1362–1365.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133–140.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease – an update. J Crohns Colitis. 2017;11(1):26–34.
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;jjw216.
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Rencz F, Poór G, et al. Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016;75(5):942–943.
   PubMed Web of Science ®Google Scholar